Skip to main content
logo
Aktis Oncology, Inc. (AKTS)
NASDAQ: AKTS · Real-Time Price · USD
24.77
+0.67 (2.78%)
Aug 11, 2026, 4:00 PM EDT - Market closed

Aktis Oncology Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22
Market Cap
1,369----
Market Cap Growth
-----
Enterprise Value
842.320000

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22
Debt / Equity Ratio
0.020.050.040.110.01
Debt / FCF Ratio
--1.01--
Net Debt / Equity Ratio
-1.041.473.251.826.60
Net Debt / EBITDA Ratio
-2.985.652.516.57
Net Debt / FCF Ratio
-2.92-23.962.506.21
Asset Turnover
-0.020.0100
Quick Ratio
19.297.2615.7915.6924.38
Current Ratio
19.497.3715.9816.0725.11
Return on Equity (ROE)
--29.45%-25.18%-24.42%-13.71%
Return on Assets (ROA)
--25.27%-23.21%-26.70%-14.29%
Return on Invested Capital (ROIC)
--238.93%-206.95%-229.10%-295.20%
Return on Capital Employed (ROCE)
--27.61%-24.58%-27.93%-14.85%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22
Buyback Yield / Dilution
-1784.33%-15.53%-14.46%-18.90%-
Total Shareholder Return
-1784.33%-15.53%-14.46%-18.90%-
SEC Filings: 10-K · 10-Q